The impact of vildagliptin on the daily glucose profile and coronary plaque stability in impaired glucose tolerance patients with coronary artery disease: VOGUE-A multicenter randomized controlled trial.
Hiroyuki YamamotoAkihide KonishiToshiro ShinkeHiromasa OtakeMasaru KurodaTsuyoshi OsueTakahiro SawadaTomofumi TakayaHiroya KawaiNaoko HashimotoTakeshi OharaYushi HirotaKazuhiko SakaguchiTakashi OmoriWataru OgawaKen-Ichi HirataPublished in: BMC cardiovascular disorders (2021)
Vildagliptin could reduce the MAGE at 6 months and may be associated with the decreased lipid arc and increased minimum FCT of the coronary plaques in CAD patients with IGT as compared with the control group. These findings may represent its potential stabilization effect on coronary plaques, which are characteristic in this patient subset. Trial registration Registered in the UMIN clinical trial registry (UMIN000008620), Name of the registry: VOGUE trial, Date of registration: Aug 6, 2012, URL: https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000010058.
Keyphrases
- coronary artery disease
- study protocol
- clinical trial
- randomized controlled trial
- coronary artery
- phase ii
- phase iii
- double blind
- open label
- aortic stenosis
- physical activity
- minimally invasive
- systematic review
- case report
- cross sectional
- heart failure
- transcatheter aortic valve replacement
- adipose tissue
- blood pressure
- placebo controlled